Richard Burr: “I urge the committee to approve it.”

What does it mean for a small company when FDA misses these goals, and what does it mean to patients?

I am concerned Ms. Kotagal lacks impartiality to interpret the law.

Where is that money gone? How is it being spent? Where is it obligated?

Ms. Kotagal's refusal to continue these common-sense measures speaks volumes of her lack of commitment to due process and transparency.